Long‐term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5years from the French prospective registry ITP‐ritux

Rituximab is a second‐line option in adults with immune thrombocytopenia (ITP), but the estimated 5‐year response rate, only based on pooled retrospective data, is about 20%, and no studies have focused on long‐term safety. We conducted a prospective multicenter registry of 248 adults with ITP treat...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of hematology 2019-12, Vol.94 (12), p.1314-1324
Hauptverfasser:	Deshayes, Samuel, Khellaf, Mehdi, Zarour, Anissa, Layese, Richard, Fain, Olivier, Terriou, Louis, Jean‐François Viallard, Cheze, Stéphane, Graveleau, Julie, Slama, Borhane, Audia, Sylvain, Cliquennois, Manuel, Ebbo, Mikael, Guillaume Le Guenno, Salles, Gilles, Bonmati, Caroline, Teillet, France, Galicier, Lionel, Lambotte, Olivier, Hot, Arnaud, Lefrère, François, Mahévas, Matthieu, Florence Canoui‐Poitrine, Michel, Marc, Godeau, Bertrand
Format:	Artikel
Sprache:	eng
Schlagworte:	Corticosteroids Hematology Hypogammaglobulinemia Idiopathic thrombocytopenic purpura Immunotherapy Monoclonal antibodies Multivariate analysis Patients Rituximab Safety Thrombocytopenia
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Rituximab is a second‐line option in adults with immune thrombocytopenia (ITP), but the estimated 5‐year response rate, only based on pooled retrospective data, is about 20%, and no studies have focused on long‐term safety. We conducted a prospective multicenter registry of 248 adults with ITP treated with rituximab with 5 years of follow‐up to assess its long‐term safety and efficacy. The median follow‐up was 68.4 [53.7‐78.5] months. The incidence of severe infections was only 2/100 patient‐years. Profound hypogammaglobulinemia (
ISSN:	0361-8609 1096-8652
DOI:	10.1002/ajh.25632